Lacryvisc SE is a tear substitute commonly used to provide symptomatic relief in conditions associated with ocular dehydration. This product is generally considered relevant for addressing symptoms of dry eyes. The gel is considered relevant for managing symptoms that may interfere with daily comfort, focusing on maintaining general well-being across various scenarios.

The medication is commonly used to address conditions such as Dry Eye Syndrome and lachrymal insufficiency, helping with symptom clusters that include pronounced burning, grittiness, and ocular irritation. It provides supportive relief during phases when symptoms become more noticeable, such as after laser surgery or due to environmental factors.

“The product's use is relevant for providing supportive relief that generally helps patients cope more steadily with difficult episodes.”

Quick Fact: Support for Recurrent Symptoms

The product supports sustained comfort, which is useful for individuals needing sustained relief from recurrent or chronic symptoms.

Who Can and Cannot Use Lacryvisc SE

The eligibility for using Lacryvisc SE (Carbomer ophthalmic gel) is defined by official regulatory documents through strict population-based rules. This information establishes who is permitted to use the medicine and who is formally prohibited.

Populations for Whom Use is Contraindicated

Lacryvisc SE is contraindicated in any patient with a known hypersensitivity to the active substance, Carbomer (polyacrylic acid), or to any of the product's excipients. This is an absolute non-eligibility rule.

Age-Group and Conditional Rules

Use is generally permitted for the Adult population, including the elderly, as no unique restrictions are specified for older adults. For children and adolescents (up to 18 years of age), use is based on existing clinical experience; however, regulatory labels note that no formal clinical trial data are available to fully establish safety and efficacy in this age group, making use conditional.

Physiological and Contextual Restrictions

Use during pregnancy or lactation is generally not recommended. Some regulatory bodies state that safety in these circumstances has not been established, requiring caution. The gel must not be instilled while wearing soft contact lenses, as lenses must be removed before application and reinserted only after a specified period to avoid absorption of the preservative. Due to the drug's negligible systemic absorption, official documents do not list restrictions based on systemic conditions such as hepatic or renal impairment.

Interactions with other medicines and products

Lacryvisc SE (Carbomer ophthalmic gel) is an ophthalmic lubricant characterized by a negligible risk of systemic drug-drug interactions. Regulatory documents confirm that due to the high molecular weight of the Carbomer polymer, systemic absorption is minimal, meaning there are no documented interactions involving metabolic pathways (such as CYP enzymes) or drug transporters.

Documented Topical and Procedural Interactions

The only officially recognized interaction pattern is a physical interference with other topical ophthalmic preparations (eye drops and eye ointments). This is classified as a localized, pharmacodynamic effect.

This mandatory procedural rule is required because the viscous gel may prolong the ocular residence time of concomitantly applied eye drops, potentially altering their local exposure. Regulatory information does not document any formal interactions with food, alcohol, or herbal products.

Hydroxypropyl methylcellulose (HPMC), the primary constituent of Lacryvisc SE, is a cellulose ether polymer with highly specialized viscoelastic and mucoadhesive properties. Upon topical application to the ocular surface, the polymeric structure physically interacts with the tear film and the underlying epithelial glycocalyx. HPMC does not engage in receptor binding or enzymatic inhibition; its mechanism is purely surface-acting. The polymer rapidly forms a transient, protective film that adheres to the epithelial surface, increasing the density and residence time of the formulation. This physical mechanism modulates the air-corneal interface by influencing the surface tension and stabilizing the biophysical characteristics of the tear fluid. The subsequent mechanical layering prevents excessive dehydration and maintains the structural integrity of the fluid film on the globe.

Official Administration Guidelines

Lacryvisc SE (carbomer 0.2% ophthalmic gel) is administered strictly via the Topical Ocular route, meaning the gel is applied directly into the eye’s conjunctival sac. It is not for oral or other systemic use. The medicine is provided as a ready-to-use gel, and no dilution or other preparation is necessary prior to instillation.

Standard Dosage and Frequency

The standard regimen involves applying one drop or small ribbon of the gel into the affected eye(s) during each application. The frequency is described as intermittent and symptom-driven, generally involving application up to three or four times a day. The total number of daily applications is determined by the requirement for lubrication, ensuring the regimen is responsive to individual need rather than a fixed, rigid schedule.

Use in Specific Populations

Official prescribing information for the carbomer gel formulation confirms that the standard adult regimen applies without modification to older adults (geriatric population). As the product exhibits minimal systemic absorption, no specific dose adjustments are detailed for patients with hepatic or renal impairment. Use in children and adolescents is established by clinical experience at the same posology as adults.

Sequential Administration Constraint

When using multiple topical eye preparations, a specific procedural condition must be observed to maintain the gel's efficacy: Lacryvisc SE must be the last preparation applied. A separation interval of at least 15 minutes is mandatory between the instillation of the carbomer gel and any other ophthalmic drops or ointments.

Research evidence / Overview of Studies for Lacryvisc SE

Evidence for Symptomatic Relief of Dry Eye Syndrome (DES)

Research on carbomer ophthalmic gels, which are used as a tear substitute, has primarily was studied for its primary regulatory indication, which is the symptomatic relief of dry eye. The research foundation includes Randomized Controlled Trials (RCTs), which have involved comparisons against an inactive substance (placebo) or against other ocular lubricating preparations. These studies were conducted during periods of increased symptom activity and typically included adult populations with varying levels of dry eye severity.

In these studies, researchers monitored changes in patient-reported outcomes describing perceived discomfort. These outcomes measured how symptoms evolved in the observed populations during the short-term follow-up periods examined. This included physical discomforts like ocular dryness, grittiness, and irritation. Findings describe patterns observed in the studies where reports of these specific symptoms evolved during the observed time. Furthermore, research explored changes in objective ocular surface measures such as the Tear Film Break-Up Time (TBUT), a measure that was monitored in the studies.

However, the evidence quality varies across studies when looking at other objective clinical signs. For example, some clinical trials reported mixed findings or variability in the measurements taken for ocular surface staining scores and tear volume (Schirmer’s test). Research provides context but not individual predictions. The findings help contextualize how patients reported their experience but do not guarantee uniform change across all clinical measures.

Long-Term Studies and Follow-Up Data

The majority of the controlled research available for carbomer gels, like other products in the artificial tear class, focused on research exploring short-term symptom changes. The follow-up durations were limited, with many RCTs observing patient responses over periods of four to eight weeks. While this research provides insight into short-term changes, it means that data derived from settings with varying symptom burdens over many months remains less extensive.

There is limited information for long-term outcomes regarding the sustained maintenance of symptom relief. The existing research primarily focuses on short-term data, meaning that long-term effects are not fully established and controlled follow-up durations were limited.

Evidence in Specific Patient Groups

The clinical research for Lacryvisc SE was primarily applied in studies examining patient-reported experiences in the general adult population diagnosed with dry eye syndrome. This includes individuals with conditions characterized by fluctuating or episodic manifestations related to tear deficiency and those with conditions where symptoms may vary in intensity.

Data for certain groups remain insufficient. For instance, there is limited information specifically from clinical trials evaluating the use of the carbomer gel in pediatric patients. Similarly, specific, targeted research exploring the evidence base for groups defined by other medical conditions is also limited. Therefore, results apply only to the populations studied in the reported clinical trials.

What is Still Uncertain About the Research for Lacryvisc SE

The research landscape, while containing numerous short-term RCTs, still presents several research limitation frames. One key uncertainty lies in the inconsistent findings reported across certain objective ocular tests, such as those measuring tear volume or surface staining, where results did not consistently align with the patient-reported outcomes.

Furthermore, comparative evidence is lacking against certain other ocular lubricating preparations. The long-term effects are not fully established in controlled settings, meaning that the durability of reported outcomes over multiple years is an area where certainty remains low. Evidence highlights what is known — and what is still uncertain, and confirms that the current body of research focuses heavily on assessing short-term, episodic symptom patterns.

Common questions about Lacryvisc SE (FAQ)

Q: Does Lacryvisc SE blur my vision when I first put it in?

Regulatory documents list blurred vision as a very common adverse effect immediately following application. This effect is described as transient, meaning it is expected to be temporary, and is an attributed result of the gel's highly viscous nature.

Q: How long does the effect of Lacryvisc SE usually last?

Studies examining similar carbomer gels indicate the product provides a prolonged contact time on the eye surface. Research suggests an ocular residence time of approximately up to 90 minutes. Some research has observed maintenance of tear film stability over periods extending up to six hours in observed populations; however, individual experience varies.

Q: Is Lacryvisc SE safe to use during pregnancy or breastfeeding?

Safety during pregnancy and breastfeeding has not been established through formal studies. While the body's absorption is considered negligible, official product information advises that caution should be exercised. The use of this product during these periods should be discussed with a healthcare professional before application.

Q: Is Lacryvisc SE meant for short-term or continuous use?

Regulatory information indicates that the duration of treatment can be extended beyond 30 days following consultation with a medical professional. Official documentation states that application frequency is driven by the individual requirement for lubrication.

Q: How quickly does Lacryvisc SE start to feel soothing?

Clinical research has noted patterns of change in subjective symptoms (such as discomfort) within observed patient populations. While the onset of relief varies individually, improvements in patient-reported symptoms have been observed in clinical settings over periods such as ten days.

Q: Does Lacryvisc SE interact with any commonly used nasal sprays or oral antihistamines?

Official regulatory documents indicate that there are no clinically relevant interactions involving systemic medications such as oral antihistamines or nasal sprays. This is due to the carbomer's high molecular weight, which results in negligible absorption into the body.

Q: Is Lacryvisc SE a treatment or just symptom relief?

Lacryvisc SE is classified as a tear substitute and an indifferent preparation. Its official regulatory purpose is defined as providing symptomatic relief for the dryness, irritation, and grittiness associated with dry eye syndrome.

Q: Why are there different strengths of similar gel eye drops?

The different strengths relate to the viscosity or thickness of the gel. Regulatory information notes that the varying viscosities of these products are linked to their pharmacological properties. A higher viscosity is associated with a prolonged contact time on the eye surface.

Q: Is Lacryvisc SE thicker than standard liquid eye drops?

Yes, the product is formulated as a highly viscous gel. Regulatory data reports its viscosity is significantly greater than that of conventional liquid artificial tear solutions, a characteristic contributing to its prolonged contact time on the eye's surface.

Q: What age group is the primary focus of the research into Lacryvisc SE?

While clinical experience supports the use of the product in children and adolescents, the primary body of controlled research and clinical trials has focused on assessing the effects and safety in the general adult population.

Q: Is headache a possible listed side effect of Lacryvisc SE?

Headache is not listed as a documented adverse reaction in the frequency tables of regulatory product information for this ophthalmic gel formulation.

Q: How does Lacryvisc SE compare to similar products in terms of viscosity?

Official documents describe this product as possessing a higher viscosity compared to conventional artificial tear solutions. This specific characteristic is associated with the product's prolonged contact time on the eye surface, which assists in stabilizing the tear film.

Storage Conditions and Stability

Lacryvisc SE must be stored at room temperature, away from excess heat and moisture, with a maximum storage temperature not above 30 C. The container must be kept perfectly closed after each use to maintain sterility. The product must be discarded 4 weeks after first opening the tube, regardless of how much gel remains, and should never be used past the expiration date printed on the carton.

Child Safety and Disposal

The ophthalmic gel must be kept out of the sight and reach of children at all times. Official regulatory instructions prohibit disposing of the container and any unused gel through wastewater or general household waste. Instead, all unneeded medication must be returned for disposal at a designated pharmaceutical collection point.